Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

BLLN vs VCYT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

VCYT Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 5–5 Matrix Metrics)

VCYT Overall Winner 6-Pillar Tally: BLLN 3 – 3 VCYT Matrix Metrics: BLLN 5 – 5 VCYT

As of Nov 16, 2026, Veracyte, Inc. (VCYT) is the stronger overall head-to-head candidate over BillionToOne, Inc. (BLLN) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). BLLN carries a Unified Composite Score of 45.8/100 (HOLD) at $96.31 (61.3x Forward P/E, 10.2% operating margin), whereas VCYT carries 49.1/100 (HOLD) at $24.01 (15.3x Forward P/E, 15.0% operating margin).

  • Growth vs. Quality Trade-Off: VCYT earns the overall head-to-head edge with a stronger Unified Composite Score (49.1/100 HOLD vs. BLLN 45.8/100 HOLD) and 3.01β · 199% Vol risk profile, whereas BLLN leads top-line expansion (+47.2% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: BLLN is currently in a Breakdown options structure phase (RSI 34.4); meanwhile VCYT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 27.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BLLN vs VCYT
BLLN US Equity
BillionToOne, Inc.
Services-Medical Laboratories
$96.31
-8.41% 1D
Market Cap $5.0B
TTM Revenue $437M
Forward P/E 61.3x
Beta / 30D Vol 1.44β · 42% Vol
Unified Composite Score
45.8 / 100 HOLD
Tech 27.0 Fund 53.0 Flow 71.0 Mom 70.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 34
RSI-14: 34.4 · SMA20: $109.99 · SMA50: $106.93
VCYT NASDAQ Head-to-Head Winner
Veracyte, Inc.
Services-Medical Laboratories
$24.01
-1.32% 1D
Market Cap $2.0B
TTM Revenue $582M
Forward P/E 15.3x
Beta / 30D Vol 3.01β · 199% Vol
Unified Composite Score
49.1 / 100 HOLD
Tech 55.0 Fund 56.0 Flow 57.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.8%), weak momentum, RSI 28
RSI-14: 27.8 · SMA20: $39.20 · SMA50: $41.79

6-Pillar Scorecard Institutional Category Breakdown (BLLN 3 – 3 VCYT)

Columns: Metric · BLLN · VCYT
1. Valuation Multiples VCYT
Forward P/E 61.3x 15.3x
Trailing P/E 114.3x 15.8x
PEG Ratio N/M N/M
EV / Revenue 10.5x 3.1x
2. Growth & Scale BLLN
Revenue Growth (YoY) +47.2% +15.1%
Earnings Growth (YoY) +220.0% +58.3%
TTM Revenue (USD) $437M $582M
Market Cap $5.0B $2.0B
3. Profitability & Quality VCYT
Gross Margin 71.4% 74.2%
Operating Margin 10.2% 15.0%
Net Profit Margin 10.5% 21.8%
Return on Equity (ROE) 13.2% 9.4%
4. Balance Sheet & Cash Flow VCYT
Cash Generation (TTM) $34M $162M
Cash Flow Margin 7.8% 27.8%
Net Cash / Leverage $421M Net Cash $159M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning BLLN
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 113.8% (26th %ile) 197.3% (47th %ile)
Put/Call OI Skew 1.21x (Put-Skewed) 0.01x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Neutral DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat BLLN
OpEx & R&D Intensity 61.2% of Rev ($267M) 59.2% of Rev ($344M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Diagnostics & Research Operator Diagnostics & Research Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BLLN (5) vs VCYT (5)
Institutional Metric BLLN VCYT Criterion Row Edge
Market Capitalization
Scale
$5.0B $2.0B Larger Scale BLLN
Trailing P/E Ratio
Valuation
114.3x 15.8x Lower Multiple VCYT
Forward P/E Ratio
Valuation
61.3x 15.3x Lower Multiple VCYT
Revenue Growth (YoY)
Growth
+47.2% +15.1% Higher Growth BLLN
Operating Margin (TTM)
Profitability
10.2% 15.0% Higher Margin VCYT
Net Profit Margin
Profitability
10.5% 21.8% Higher Margin VCYT
Return on Equity (ROE)
Capital Efficiency
13.2% 9.4% Higher ROE BLLN
52-Week Range Position
Momentum
39% ($62–$150) 5% ($22–$61) Stronger Trend BLLN
Beta / 30D Volatility
Risk Regime
1.44β · 42% Vol 3.01β · 199% Vol Lower Realized Risk BLLN
Unified Institutional Score
Composite Signal
45.8 / 100 (HOLD) 49.1 / 100 (HOLD) Higher Composite VCYT
Trailing 12M Revenue (USD)
Operating Scale
$437M $582M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
71.4% 74.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 10.5x EV/Rev N/M PEG · 3.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$34M ($421M Net Cash) $162M ($159M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BLLN +42.48 pp
BLLN: -1.84% · VCYT: -44.32%
3M Horizon BLLN +50.44 pp
BLLN: +9.46% · VCYT: -40.98%
6M Horizon BLLN +53.97 pp
BLLN: +11.83% · VCYT: -42.14%
1Y Horizon BLLN +47.33 pp
BLLN: +7.55% · VCYT: -39.78%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period BLLN Revenue VCYT Revenue BLLN Op. Margin VCYT Op. Margin Margin Leader
FY2018 N/A $90M N/A -24.2% VCYT
FY2019 N/A $120M N/A -12.6% VCYT
FY2020 N/A $120M N/A -30.1% VCYT
FY2021 N/A $220M N/A -37.3% VCYT
FY2022 N/A $300M N/A -13.9% VCYT
FY2023 $70M $360M -96.9% -23.8% VCYT
FY2024 $150M $450M -30.9% 3.6% VCYT
FY2025 $310M $520M 5.3% 11.2% VCYT

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BLLN BREAKDOWN
78d in phase · OBV DISTRIBUTION
Current IV 113.8%
IV Percentile 26th %ile
Put/Call OI Skew 1.21x (Put-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact BLLN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
VCYT BREAKDOWN
99d in phase · OBV DISTRIBUTION
Current IV 197.3%
IV Percentile 47th %ile
Put/Call OI Skew 0.01x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact VCYT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BLLN Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $5.0B market capitalization and 10.2% operating margin.
OpEx & R&D Reinvestment 61.2% of Rev ($267M)
90D Engineering Disclosures 0 Published
VCYT Moat Profile Scale & Operating Efficiency Moat
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $2.0B market capitalization and 15.0% operating margin.
OpEx & R&D Reinvestment 59.2% of Rev ($344M)
90D Engineering Disclosures 0 Published

Investor FAQ BLLN vs VCYT Key Questions & Quantitative Answers

As of Nov 16, 2026, Veracyte, Inc. (VCYT) is the stronger overall head-to-head candidate over BillionToOne, Inc. (BLLN) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). BLLN carries a Unified Composite Score of 45.8/100 (HOLD) at $96.31 (61.3x Forward P/E, 10.2% operating margin), whereas VCYT carries 49.1/100 (HOLD) at $24.01 (15.3x Forward P/E, 15.0% operating margin). Growth vs. Quality Trade-Off: VCYT earns the overall head-to-head edge with a stronger Unified Composite Score (49.1/100 HOLD vs. BLLN 45.8/100 HOLD) and 3.01β · 199% Vol risk profile, whereas BLLN leads top-line expansion (+47.2% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: BLLN is currently in a Breakdown options structure phase (RSI 34.4); meanwhile VCYT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 27.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

BLLN leads the Growth & Scale pillar: BLLN posts +47.2% YoY revenue growth and +220.0% YoY earnings growth on $437M TTM revenue (71.4% gross margin, 10.2% operating margin), compared with VCYT at +15.1% YoY revenue growth and +58.3% YoY earnings growth on $582M TTM revenue (74.2% gross margin, 15.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), BLLN cumulative revenue shifted +342.9% while VCYT shifted +477.8%. In operating R&D and SG&A reinvestment, BLLN deploys 61.2% of Rev ($267M) (0 90-day corporate R&D disclosures) versus 59.2% of Rev ($344M) (0 disclosures) for VCYT.

VCYT screens cheaper on headline valuation multiples. BLLN trades at 61.3x Forward P/E, 114.3x Trailing P/E, N/M PEG, and 10.5x EV/Revenue (7.8% FCF margin), whereas VCYT trades at 15.3x Forward P/E, 15.8x Trailing P/E, N/M PEG, and 3.1x EV/Revenue (27.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BLLN (13.2% ROE) versus VCYT (9.4% ROE) capital efficiency.

In options market volatility and institutional positioning, BLLN carries 113.8% implied volatility (26th %ile, Balanced (25th–60th %ile)), a 1.21x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.44β · 42% Vol realized risk). By comparison, VCYT carries 197.3% implied volatility (47th %ile, Balanced (25th–60th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (3.01β · 199% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.